Press Resease

Oral Antidiabetic Drugs Market - Global Industry Analysis

Oral Antidiabetic Drugs Market By Drugs Class (Sulfonylureas (Glimepiride, Gliclazide, Glyburide, Others), Meglitinides, Repaglinide, Nateglinide, Biguanides (Metformin, Others), Alpha-glucosidase inhibitors (Acarbose, Voglibose, Others), Others, By Type (Type 1 Diabetes, Type 2 diabetes), By End User (Hospital, Pharmacy Store, Drug Store, Diabetics Treatment Centres, Others) - Global Industry Perspective, Comprehensive Analysis And Forecast, 2020 – 2028

Published Date: 18-Oct-2021 Category: Pharmaceutical Report Format : PDF Pages: 150 Report Code: ZMR-687 Status : Published

The global oral antidiabetic drugs market accounted for USD 43.01 Billion in 2020 and is expected to reach USD 66.30 Billion by 2028, growing at a CAGR of 5.6% from 2021 to 2028.

Description

Market Overview

In terms of revenue, the global oral antidiabetic drugs marketaccounted for USD 43.01 Billion in 2020 and is expected to reachUSD 66.30 Billion by 2028, growing at a CAGR of 5.6% from 2021 to2028.

According to the International Diabetes Federation (IDF) in2016, it was estimated, approximately 463 million people suffereddiabetes globally, with 90% of the cases of type 2 diabetes. In2017, in the United States, the cost of diabetes was USD 327billion.

Diabetes is a chronic disease that occurs when the pancreas doesnot produce enough insulin or when the body cannot effectively usethe insulin. Hyperglycemia, or raised blood sugar, is a commoneffect of uncontrolled diabetes and over time leads to seriousdamage to many of the body's systems, especially the nerves andblood vessels. Owing to the presence of the large base of theparticipants the Oral antidiabetic drugs Market is expected toboost the Market. Some of the major players of the oralantidiabetic drugs market are Sanofi S.A., Eli Lilly and Company,AstraZeneca plc, Astellas Pharma Inc., Johnson & Johnson (JanssenPharmaceuticals), Boehringer Ingelheim, Merck And Co., Takeda,Bristol Myers Squibb, Novartis, Pfizer. Now a days, due to theinnovation of new drugs and advanced technology, and ease to use,it is expected to enhance the growth of the market.

Global Oral Antidiabetic Drugs Market Size

COVID-19 Impact Analysis

Coronavirus viral spreading (COVID-19) has positively impactedthe worldwide demand for Oral antidiabetic drugs Market. Owing tothe COVID-19 lockdown in the various countries, the demand of thedrugs for chronic diseases have been increased. The people havingmedications for chronic diseases have managed to store the drugsfor overall the period of lockdown. Due to the COVID-19 lockdownthe physical activities of peoples have been decreased which haveled to increase in the Diabetes, obesity and various diseases.Hence the base of the participants of diabetic patients isincreasing which can be the diver for the Oral antidiabetic drugsMarket over the forecast period.

Growth Factors

According to the World Health Organization (WHO), rising numberof incidences of diabetes is one of the important drivers fordiabetes drugs market. In addition, research & developmentinitiatives, technological advancements, and improved healthcarefacilities are the key factors fueling the growth of the market.Changing lifestyle and the adoption of fast food that has resultedin the high prevalence of obesity is expected to fueling the demandof the market. Owing to the presence of the large base of theparticipants the Oral antidiabetic drugs Market is expected toboost the market. Owing to the busy lifestyle and rising demandfor fast-food is resulting in diabetes which isexpected to Increase the demand for anti-diabetic drugsover the forecast period. Also, increasing cases of type2 diabetes among the population due to lack ofphysical activity is predicted to increase the demand forthe anti-diabetic drug. Due to the growing use of artificialsweeteners Such as aspartame in the food materials, as a substitutefor sugar is anticipated to have positive impact on the growth ofthe Oral antidiabetic drugs Market.

However, stringent regulatory environment and time-consumingapproval process are the major restraining factors that arehampering the growth of the diabetes drugs market. Due to the highcost, a large population cannot afford the treatment and isdepending on generic drugs, ultimately affecting the growth of theoverall market.

Report Scope:

Report AttributeDetails
Base Year2020
Historic Years2016 - 2020
Forecast Years2021 - 2028
Segments CoveredBy Product Type, By Application, and By End Use
Forecast UnitsValue (USD Billion), and Volume (Units)
Quantitative UnitsRevenue in USD million/billion and CAGR from 2021 to 2028
Regions CoveredNorth America, Europe, Asia Pacific, Latin America, and MiddleEast & Africa, and Rest of World
Countries CoveredU.S., Canada, Mexico, U.K., Germany, France, Italy, Spain,China, India, Japan, South Korea, Brazil, Argentina, GCC Countries,and South Africa, among others
Number of Companies Covered10 companies with scope for including additional 15 companiesupon request
Report CoverageMarket growth drivers, restraints, opportunities, Porter’s fiveforces analysis, PEST analysis, value chain analysis, regulatorylandscape, market attractiveness analysis by segments and region,company market share analysis, and COVID-19 impact analysis.
Customization ScopeAvail customized purchase options to meet your exact researchneeds.

By Drugs Class Segment Analysis Preview:

Based on the oral drugs, the market is segmented intoalpha-glucosidase inhibitors, biguanides, bile acid sequestrants,dpp-4 inhibitors, meglitinides and d-phenylalanine derivatives,sulfonylureas and others., Biguanides is expected to hold majormarket share owing to helps to lower bloodglucose levels throughout the day. 

On the basis of type, the market is segmented into type 1diabetes and type 2 diabetes. Type 2 is expected to hold majormarket share owing to 90 to 95% people suffered from type 2diabetes. Owing to the presence of the large base of theparticipants these segment is expected to dominate the oral antidiabetic drugs market.

Global Oral Antidiabetic Drugs Market Share

Regional Analysis Preview

North America is expected hold major market share in globaldiabetes care market. This is attributed to, increasing theprevalence of genetic and chronic diseases. Furthermore increasingthe population of obesity is leading cause of diabetes prevalenceis boosting the growth of market.

Europe is expected to second leading region in global diabetescare market. This is attributed to increasing prevalence ofdiabetes diseases on account of increasing environmental pollutionand genetic disorders.

Asia Pacific is expected to fastest growing market due to thepresence of huge opportunity for the development of the market.This is attributed to increasing prevalence of genetic diseases isdriving the growth of the diabetes care market. Additionally,government support to the diabetes care patient is supporting thegrowth of the diabetes care market. Constructive government schemessuch as Ayushman Bharat-National Health Protection Mission,Indradhanus will also contribute to drive the demand; ultimatelycontributing to the market growth.

Key Market Players & Competitive Landscape

Some of key players in oral antidiabetic drugs market are,

  1. Sanofi S.A.
  2. Eli Lilly and Company
  3. AstraZeneca plc
  4. Astellas Pharma Inc.
  5. Johnson & Johnson (Janssen Pharmaceuticals)
  6. Boehringer Ingelheim
  7. Merck And Co.
  8. Takeda
  9. Bristol Myers Squibb
  10. Novartis
  11. Pfizer

The Oral antidiabetic drugs Market is segmented asfollows:

By Drugs Class

  • Sulfonylureas (Glimepiride, Gliclazide, Glyburide, Others)
  • Meglitinides
  • Repaglinide
  • Nateglinide
  • Biguanides (Metformin, Others)
  • Alpha-glucosidase inhibitors (Acarbose, Voglibose, Others)
  • Others

By Type

  • Type 1 Diabetes
  • Type 2 diabetes

By End User

  • Hospital
  • Pharmacy Store
  • Drug Store
  • Diabetics Treatment Centres
  • Others

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • CHAPTER NO. 1: INTRODUCTION
    • 1.1. Report Description
      • 1.1.1. Purpose of the Report
      • 1.1.2. USP & Key Offerings
    • 1.2. Key Benefits for Stakehulders
    • 1.3. Target Audience
    • 1.4. Report Scope
  • CHAPTER NO. 2: EXECUTIVE SUMMARY
    • 2.1. Key Findings
      • 2.1.1. Top Investment Pockets
        • 2.1.1.1. Market Attractiveness Analysis, By Drugs Class Analysis
        • 2.1.1.2. Market Attractiveness Analysis, By Type
        • 2.1.1.3. Market Attractiveness Analysis, By End User
        • 2.1.1.4. Market Attractiveness Analysis, By Region
    • 2.2. Market Snapshot
    • 2.3. Global Oral antidiabetic drugs Market, 2016 – 2028 (USD Million)
    • 2.4. Insights from Primary Respondents
  • CHAPTER NO. 3: COVID 19 IMPACT ANALYSIS
    • 3.1. Impact Assessment of COVID-19 Pandemic, By Region
      • 3.1.1. North America
      • 3.1.2. Europe
      • 3.1.3. Asia Pacific
      • 3.1.4. Latin America
      • 3.1.5. The Middle-East and Africa
    • 3.2. Quarterly Market Revenue and Forecast by Region 2020 & 2021
    • 3.3. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
    • 3.4. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
    • 3.5. Key Strategies Undertaken by Companies to Tackle COVID-19
      • 3.5.1. Company Quarterly Revenue Analysis, 2019 & 2020
    • 3.6. Short Term Dynamics
    • 3.7. Long Term Dynamics
  • CHAPTER NO. 4: ORAL ANTIDIABETIC DRUGS MARKET – BY DRUGS CLASS ANALYSIS SEGMENT ANALYSIS
    • 4.1. Overview
      • 4.1.1. Market Revenue Share, By Drugs Class Analysis, 2020 & 2028
    • 4.2. Meglitinides
      • 4.2.1. Market Size and Forecast, By Region (USD Million)
      • 4.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.3. Repaglinide
      • 4.3.1. Market Size and Forecast, By Region (USD Million)
      • 4.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.4. Nateglinide
      • 4.4.1. Market Size and Forecast, By Region (USD Million)
      • 4.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.5. Sulfonylureas (Glimepiride, Gliclazide, Glyburide, Others)
      • 4.5.1. Market Size and Forecast, By Region (USD Million)
      • 4.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.5.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.6. Biguanides(Metformin, Others)
      • 4.6.1. Market Size and Forecast, By Region (USD Million)
      • 4.6.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.6.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.7. Alpha-glucosidase inhibitors (Acarbose, Voglibose, Others)
      • 4.7.1. Market Size and Forecast, By Region (USD Million)
      • 4.7.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.7.3. Key Market Trends, Growth Factors, & Opportunities
    • 4.8. Others
      • 4.8.1. Market Size and Forecast, By Region (USD Million)
      • 4.8.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 4.8.3. Key Market Trends, Growth Factors, & Opportunities
  • CHAPTER NO. 5: ORAL ANTIDIABETIC DRUGS MARKET – BY TYPE SEGMENT ANALYSIS
    • 5.1. Overview
      • 5.1.1. Market Revenue Share, By Type, 2020 & 2028
    • 5.2. Type 1 Diabetes
      • 5.2.1. Market Size and Forecast, By Region (USD Million)
      • 5.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 5.3. Type 2 diabetes
      • 5.3.1. Market Size and Forecast, By Region (USD Million)
      • 5.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 5.3.3. Key Market Trends, Growth Factors, & Opportunities
  • CHAPTER NO. 6: ORAL ANTIDIABETIC DRUGS MARKET – BY END USER SEGMENT ANALYSIS
    • 6.1. Overview
      • 6.1.1. Market Revenue Share, By End User, 2020 & 2028
    • 6.2. Hospital
      • 6.2.1. Market Size and Forecast, By Region (USD Million)
      • 6.2.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.2.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.3. Pharmacy Store
      • 6.3.1. Market Size and Forecast, By Region (USD Million)
      • 6.3.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.3.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.4. Drug Store
      • 6.4.1. Market Size and Forecast, By Region (USD Million)
      • 6.4.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.4.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.5. Diabetics Treatment Centres
      • 6.5.1. Market Size and Forecast, By Region (USD Million)
      • 6.5.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.5.3. Key Market Trends, Growth Factors, & Opportunities
    • 6.6. Others
      • 6.6.1. Market Size and Forecast, By Region (USD Million)
      • 6.6.2. Comparative Revenue Analysis, By Country, 2020 & 2028
      • 6.6.3. Key Market Trends, Growth Factors, & Opportunities
  • CHAPTER NO. 7: ORAL ANTIDIABETIC DRUGS MARKET – REGIONAL ANALYSIS
    • 7.1. Overview
      • 7.1.1. Global Market Revenue Share, By Region, 2020 & 2028
      • 7.1.2. Global Market Revenue, By Region, 2016 – 2028 (USD Million)
    • 7.2. North America
      • 7.2.1. North America Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.2.2. North America Market Revenue, By Drugs Class Analysis, 2016 – 2028
      • 7.2.3. North America Market Revenue, By Type, 2016 – 2028
      • 7.2.4. North America Market Revenue, By End User, 2016 – 2028
      • 7.2.5. U.S.
        • 7.2.5.1. U.S. Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.2.5.2. U.S. Market Revenue, By Type, 2016 – 2028
        • 7.2.5.3. U.S. Market Revenue, By End User, 2016 – 2028
      • 7.2.6. Canada
        • 7.2.6.1. Canada Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.2.6.2. Canada Market Revenue, By Type, 2016 – 2028
        • 7.2.6.3. Canada Market Revenue, By End User, 2016 – 2028
      • 7.2.7. Mexico
        • 7.2.7.1. Mexico Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.2.7.2. Mexico Market Revenue, By Type, 2016 – 2028
        • 7.2.7.3. Mexico Market Revenue, By End User, 2016 – 2028
    • 7.3. Europe
      • 7.3.1. Europe Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.3.2. Europe Market Revenue, By Drugs Class Analysis, 2016 – 2028
      • 7.3.3. Europe Market Revenue, By Type, 2016 – 2028
      • 7.3.4. Europe Market Revenue, By End User, 2016 – 2028
      • 7.3.5. Germany
        • 7.3.5.1. Germany Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.3.5.2. Germany Market Revenue, By Type, 2016 – 2028
        • 7.3.5.3. Germany Market Revenue, By End User, 2016 – 2028
      • 7.3.6. France
        • 7.3.6.1. France Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.3.6.2. France Market Revenue, By Type, 2016 – 2028
        • 7.3.6.3. France Market Revenue, By End User, 2016 – 2028
      • 7.3.7. U.K.
        • 7.3.7.1. U.K. Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.3.7.2. U.K. Market Revenue, By Type, 2016 – 2028
        • 7.3.7.3. U.K. Market Revenue, By End User, 2016 – 2028
      • 7.3.8. Italy
        • 7.3.8.1. Italy Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.3.8.2. Italy Market Revenue, By Type, 2016 – 2028
        • 7.3.8.3. Italy Market Revenue, By End User, 2016 – 2028
      • 7.3.9. Spain
        • 7.3.9.1. Spain Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.3.9.2. Spain Market Revenue, By Type, 2016 – 2028
        • 7.3.9.3. Spain Market Revenue, By End User, 2016 – 2028
      • 7.3.10. Rest of Europe
        • 7.3.10.1. Rest of Europe Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.3.10.2. Rest of Europe Market Revenue, By Type, 2016 – 2028
        • 7.3.10.3. Rest of Europe Market Revenue, By End User, 2016 – 2028
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.4.2. Asia Pacific Market Revenue, By Drugs Class Analysis, 2016 – 2028
      • 7.4.3. Asia Pacific Market Revenue, By Type, 2016 – 2028
      • 7.4.4. Asia Pacific Market Revenue, By End User, 2016 – 2028
      • 7.4.5. China
        • 7.4.5.1. China Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.4.5.2. China Market Revenue, By Type, 2016 – 2028
        • 7.4.5.3. China Market Revenue, By End User, 2016 – 2028
      • 7.4.6. Japan
        • 7.4.6.1. Japan Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.4.6.2. Japan Market Revenue, By Type, 2016 – 2028
        • 7.4.6.3. Japan Market Revenue, By End User, 2016 – 2028
      • 7.4.7. India
        • 7.4.7.1. India Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.4.7.2. India Market Revenue, By Type, 2016 – 2028
        • 7.4.7.3. India Market Revenue, By End User, 2016 – 2028
      • 7.4.8. South Korea
        • 7.4.8.1. South Korea Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.4.8.2. South Korea Market Revenue, By Type, 2016 – 2028
        • 7.4.8.3. South Korea Market Revenue, By End User, 2016 – 2028
      • 7.4.9. South-East Asia
        • 7.4.9.1. South-East Asia Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.4.9.2. South-East Asia Market Revenue, By Type, 2016 – 2028
        • 7.4.9.3. South-East Asia Market Revenue, By End User, 2016 – 2028
      • 7.4.10. Rest of Asia Pacific
        • 7.4.10.1. Rest of Asia Pacific Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.4.10.2. Rest of Asia Pacific Market Revenue, By Type, 2016 – 2028
        • 7.4.10.3. Rest of Asia Pacific Market Revenue, By End User, 2016 – 2028
    • 7.5. Latin America
      • 7.5.1. Latin America Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.5.2. Latin America Market Revenue, By Drugs Class Analysis, 2016 – 2028
      • 7.5.3. Latin America Market Revenue, By Type, 2016 – 2028
      • 7.5.4. Latin America Market Revenue, By End User, 2016 – 2028
      • 7.5.5. Brazil
        • 7.5.5.1. Brazil Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.5.5.2. Brazil Market Revenue, By Type, 2016 – 2028
        • 7.5.5.3. Brazil Market Revenue, By End User, 2016 – 2028
      • 7.5.6. Argentina
        • 7.5.6.1. Argentina Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.5.6.2. Argentina Market Revenue, By Type, 2016 – 2028
        • 7.5.6.3. Argentina Market Revenue, By End User, 2016 – 2028
      • 7.5.7. Rest of Latin America
        • 7.5.7.1. Rest of Latin America Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.5.7.2. Rest of Latin America Market Revenue, By Type, 2016 – 2028
        • 7.5.7.3. Rest of Latin America Market Revenue, By End User, 2016 – 2028
    • 7.6. The Middle-East and Africa
      • 7.6.1. The Middle-East and Africa Market Revenue, By Country, 2016 – 2028 (USD Million)
      • 7.6.2. The Middle-East and Africa Market Revenue, By Drugs Class Analysis, 2016 – 2028
      • 7.6.3. The Middle-East and Africa Market Revenue, By Type, 2016 – 2028
      • 7.6.4. The Middle-East and Africa Market Revenue, By End User, 2016 – 2028
      • 7.6.5. GCC Countries
        • 7.6.5.1. GCC Countries Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.6.5.2. GCC Countries Market Revenue, By Type, 2016 – 2028
        • 7.6.5.3. GCC Countries Market Revenue, By End User, 2016 – 2028
      • 7.6.6. South Africa
        • 7.6.6.1. South Africa Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.6.6.2. South Africa Market Revenue, By Type, 2016 – 2028
        • 7.6.6.3. South Africa Market Revenue, By End User, 2016 – 2028
      • 7.6.7. Rest of Middle-East Africa
        • 7.6.7.1. Rest of Middle-East Africa Market Revenue, By Drugs Class Analysis, 2016 – 2028
        • 7.6.7.2. Rest of Middle-East Africa Market Revenue, By Type, 2016 – 2028
        • 7.6.7.3. Rest of Middle-East Africa Market Revenue, By End User, 2016 – 2028
  • CHAPTER NO. 8: ORAL ANTIDIABETIC DRUGS MARKET – INDUSTRY ANALYSIS
    • 8.1. Introduction
    • 8.2. Market Drivers
      • 8.2.1. Driving Factor 1 Analysis
      • 8.2.2. Driving Factor 2 Analysis
    • 8.3. Market Restraints
      • 8.3.1. Restraining Factor Analysis
    • 8.4. Market Opportunities
      • 8.4.1. Market Opportunity Analysis
    • 8.5. Porter’s Five Forces Analysis
    • 8.6. PEST Analysis
    • 8.7. Regulatory Landscape
    • 8.8. Technulogy Landscape
    • 8.9. Regional Market Trends
      • 8.9.1. North America
      • 8.9.2. Europe
      • 8.9.3. Asia Pacific
      • 8.9.4. Latin America
      • 8.9.5. The Middle-East and Africa
    • 8.10. Pricing Analysis
    • 8.11. Value Chain Analysis
    • 8.12. Downstream Buyers
    • 8.13. Distributors/Traders List
  • CHAPTER NO. 9: COMPETITIVE LANDSCAPE
    • 9.1. Company Market Share Analysis – 2019
      • 9.1.1. Global Oral antidiabetic drugs Market: Company Market Share, 2019
      • 9.1.2. Global Oral antidiabetic drugs Market, Company Market Revenue, 2016 – 2019 (USD Million)
      • 9.1.3. Global Oral antidiabetic drugs Market, Company Y-o-Y Growth, 2017 – 2019 (%)
      • 9.1.4. Global Oral antidiabetic drugs Market: Radar Determinant Chart, 2019
    • 9.2. Strategic Developments
      • 9.2.1. Acquisitions & Mergers
      • 9.2.2. New Product Launch
      • 9.2.3. Regional Expansion
    • 9.3. Company Strategic Developments – Heat Map Analysis
  • CHAPTER NO. 10: COMPANY PROFILES
    • 10.1. Sanofi S.A.
      • 10.1.1. Company Overview
      • 10.1.2. Key Executives
      • 10.1.3. Product Portfulio
      • 10.1.4. Financial Overview
      • 10.1.5. Operating Business Segments
      • 10.1.6. Business Performance
      • 10.1.7. Recent Developments
    • 10.2. Eli Lilly and Company
    • 10.3. AstraZeneca plc
    • 10.4. Astellas Pharma Inc.
    • 10.5. Johnson & Johnson (Janssen Pharmaceuticals)
    • 10.6. Boehringer Ingelheim
    • 10.7. Merck And Co.
    • 10.8. Takeda
    • 10.9. Bristul Myers Squibb
    • 10.10. Novartis
    • 10.11. Pfizer
  • CHAPTER NO. 11: MARKETING STRATEGY ANALYSIS
    • 11.1. Marketing Channel
    • 11.2. Direct Marketing
    • 11.3. Indirect Marketing
    • 11.4. Marketing Channel Development Trends
    • 11.5. Economic/Pulitical Environmental Change
  • CHAPTER NO. 12: RESEARCH METHODulOGY
    • 12.1. Research Methodulogy
    • 12.2. Phase I - Secondary Research
    • 12.3. Phase II - Data Modeling
      • 12.3.1. Company Share Analysis Model
      • 12.3.2. Revenue Based Modeling
    • 12.4. Phase III - Primary Research
    • 12.5. Research Limitations
      • 12.5.1. Assumptions

List of Figures    

FIG NO. 1. Market Attractiveness Analysis, By Drugs Class Analysis
FIG NO. 2. Market Attractiveness Analysis, By Type
FIG NO. 3. Market Attractiveness Analysis, By End User
FIG NO. 4. Market Attractiveness Analysis, By Region
FIG NO. 5. Global Oral antidiabetic drugs Market Revenue, 2016 – 2028 (USD Million)
FIG NO. 6. Impact of COVID-19 Pandemic in North America Countries
FIG NO. 7. Market Revenue Share, By Drugs Class Analysis, 2020 & 2028
FIG NO. 8. Global Oral antidiabetic drugs Market for Meglitinides, Revenue (USD Million) 2016 – 2028
FIG NO. 9. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Meglitinides, By Country, 2020 & 2028
FIG NO. 10. Global Oral antidiabetic drugs Market for Repaglinide, Revenue (USD Million) 2016 – 2028
FIG NO. 11. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Repaglinide, By Country, 2020 & 2028
FIG NO. 12. Global Oral antidiabetic drugs Market for Nateglinide, Revenue (USD Million) 2016 – 2028
FIG NO. 13. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Nateglinide, By Country, 2020 & 2028
FIG NO. 14. Global Oral antidiabetic drugs Market for Sulfonylureas (Glimepiride, Gliclazide, Glyburide, Others), Revenue (USD Million) 2016 – 2028
FIG NO. 15. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Sulfonylureas (Glimepiride, Gliclazide, Glyburide, Others), By Country, 2020 & 2028
FIG NO. 16. Global Oral antidiabetic drugs Market for Biguanides(Metformin, Others), Revenue (USD Million) 2016 – 2028
FIG NO. 17. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Biguanides(Metformin, Others), By Country, 2020 & 2028
FIG NO. 18. Global Oral antidiabetic drugs Market for Alpha-glucosidase inhibitors (Acarbose, Voglibose, Others), Revenue (USD Million) 2016 – 2028
FIG NO. 19. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Alpha-glucosidase inhibitors (Acarbose, Voglibose, Others), By Country, 2020 & 2028
FIG NO. 20. Global Oral antidiabetic drugs Market for Others, Revenue (USD Million) 2016 – 2028
FIG NO. 21. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Others, By Country, 2020 & 2028
FIG NO. 22. Market Revenue Share, By Type, 2020 & 2028
FIG NO. 23. Global Oral antidiabetic drugs Market for Type 1 Diabetes, Revenue (USD Million) 2016 – 2028
FIG NO. 24. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Type 1 Diabetes, By Country, 2020 & 2028
FIG NO. 25. Global Oral antidiabetic drugs Market for Type 2 diabetes, Revenue (USD Million) 2016 – 2028
FIG NO. 26. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Type 2 diabetes, By Country, 2020 & 2028
FIG NO. 27. Market Revenue Share, By End User, 2020 & 2028
FIG NO. 28. Global Oral antidiabetic drugs Market for Hospital, Revenue (USD Million) 2016 – 2028
FIG NO. 29. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Hospital, By Country, 2020 & 2028
FIG NO. 30. Global Oral antidiabetic drugs Market for Pharmacy Store, Revenue (USD Million) 2016 – 2028
FIG NO. 31. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Pharmacy Store, By Country, 2020 & 2028
FIG NO. 32. Global Oral antidiabetic drugs Market for Drug Store, Revenue (USD Million) 2016 – 2028
FIG NO. 33. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Drug Store, By Country, 2020 & 2028
FIG NO. 34. Global Oral antidiabetic drugs Market for Diabetics Treatment Centres, Revenue (USD Million) 2016 – 2028
FIG NO. 35. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Diabetics Treatment Centres, By Country, 2020 & 2028
FIG NO. 36. Global Oral antidiabetic drugs Market for Others, Revenue (USD Million) 2016 – 2028
FIG NO. 37. Comparative Revenue Analysis of Oral antidiabetic drugs Market for Others, By Country, 2020 & 2028
FIG NO. 38. Global Oral antidiabetic drugs Market Revenue Share, By Region, 2020 & 2028
FIG NO. 39. North America Oral antidiabetic drugs Market Revenue, 2016 - 2028 (USD Million)
FIG NO. 40. Porter’s Five Forces Analysis for Global Oral antidiabetic drugs Market
FIG NO. 41. PEST Analysis for Global Oral antidiabetic drugs Market
FIG NO. 42. Pricing Analysis for Global Oral antidiabetic drugs Market
FIG NO. 43. Value Chain Analysis for Global Oral antidiabetic drugs Market
FIG NO. 44. Company Share Analysis, 2019
FIG NO. 45. Radar Determinant Chart, 2019
FIG NO. 46. Company Strategic Developments – Heat Map Analysis
FIG NO. 47. Sanofi S.A. Business Segment Revenue Share, 2020 (%)
FIG NO. 48. Sanofi S.A. Geographical Segment Revenue Share, 2020 (%)
FIG NO. 49. Market Channels
FIG NO. 50. Marketing Channel Development Trend
FIG NO. 51. Growth in World Gross Product, 2008-2018
FIG NO. 52. Research Methodology – Detailed View
FIG NO. 53. Research Methodology
 


List of Tables 

TABLE NO. 1 Global Oral antidiabetic drugs Market: Snapshot
TABLE NO. 2 Quarterly Oral antidiabetic drugs Market Revenue by Region, 2020
TABLE NO. 3 Quarterly Oral antidiabetic drugs Market Revenue Forecast by Region, 2021
TABLE NO. 4 Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Million)
TABLE NO. 5 Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Million)
TABLE NO. 6 Global Oral antidiabetic drugs Market for Meglitinides, by Region, 2016 – 2028 (USD Million)
TABLE NO. 7 Global Oral antidiabetic drugs Market for Repaglinide, by Region, 2016 – 2028 (USD Million)
TABLE NO. 8 Global Oral antidiabetic drugs Market for Nateglinide, by Region, 2016 – 2028 (USD Million)
TABLE NO. 9 Global Oral antidiabetic drugs Market for Sulfonylureas (Glimepiride, Gliclazide, Glyburide, Others), by Region, 2016 – 2028 (USD Million)
TABLE NO. 10 Global Oral antidiabetic drugs Market for Biguanides(Metformin, Others), by Region, 2016 – 2028 (USD Million)
TABLE NO. 11 Global Oral antidiabetic drugs Market for Alpha-glucosidase inhibitors (Acarbose, Voglibose, Others), by Region, 2016 – 2028 (USD Million)
TABLE NO. 12 Global Oral antidiabetic drugs Market for Others, by Region, 2016 – 2028 (USD Million)
TABLE NO. 13 Global Oral antidiabetic drugs Market for Type 1 Diabetes, by Region, 2016 – 2028 (USD Million)
TABLE NO. 14 Global Oral antidiabetic drugs Market for Type 2 diabetes, by Region, 2016 – 2028 (USD Million)
TABLE NO. 15 Global Oral antidiabetic drugs Market for Hospital, by Region, 2016 – 2028 (USD Million)
TABLE NO. 16 Global Oral antidiabetic drugs Market for Pharmacy Store, by Region, 2016 – 2028 (USD Million)
TABLE NO. 17 Global Oral antidiabetic drugs Market for Drug Store, by Region, 2016 – 2028 (USD Million)
TABLE NO. 18 Global Oral antidiabetic drugs Market for Diabetics Treatment Centres, by Region, 2016 – 2028 (USD Million)
TABLE NO. 19 Global Oral antidiabetic drugs Market for Others, by Region, 2016 – 2028 (USD Million)
TABLE NO. 20 Global Oral antidiabetic drugs Market Revenue, By Region, 2016 – 2028 (USD Million)
TABLE NO. 21 North America Oral antidiabetic drugs Market Revenue, By Country, 2016 – 2028 (USD Million)
TABLE NO. 22 North America Oral antidiabetic drugs Market Revenue, By Drugs Class Analysis, 2016 – 2028 (USD Million)
TABLE NO. 23 North America Oral antidiabetic drugs Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 24 North America Oral antidiabetic drugs Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 25 U.S. Oral antidiabetic drugs Market Revenue, By Drugs Class Analysis, 2016 – 2028 (USD Million)
TABLE NO. 26 U.S. Oral antidiabetic drugs Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 27 U.S. Oral antidiabetic drugs Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 28 Canada Oral antidiabetic drugs Market Revenue, By Drugs Class Analysis, 2016 – 2028 (USD Million)
TABLE NO. 29 Canada Oral antidiabetic drugs Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 30 Canada Oral antidiabetic drugs Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 31 Mexico Oral antidiabetic drugs Market Revenue, By Drugs Class Analysis, 2016 – 2028 (USD Million)
TABLE NO. 32 Mexico Oral antidiabetic drugs Market Revenue, By Type, 2016 – 2028 (USD Million)
TABLE NO. 33 Mexico Oral antidiabetic drugs Market Revenue, By End User, 2016 – 2028 (USD Million)
TABLE NO. 34 Drivers for the Oral antidiabetic drugs Market: Impact Analysis
TABLE NO. 35 Restraints for the Oral antidiabetic drugs Market: Impact Analysis
TABLE NO. 36 Major Buyers of Oral antidiabetic drugs
TABLE NO. 37 Distributors/Traders List of Oral antidiabetic drugs
TABLE NO. 38 Global Oral antidiabetic drugs Market, Company Market Revenue, 2016 – 2019 (USD Million)
TABLE NO. 39 Global Oral antidiabetic drugs Market, Company Y-o-Y Growth, 2017 – 2019 (USD Million)
 

Methodology

This report is based on in-depth qualitative and quantitative analyses of the global Oral Anti-diabetic Drugs market. Zion Research has collected and analyzed key data belong to the global Oral Anti-diabetic Drugs market using a variety of methods. Quantitative analysis has been done following various projection and sampling techniques.

The qualitative analysis involved primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes were validated through experts' opinions. The market dynamics have been determined after conducting a detailed study of the micro and macroeconomic indicators of the market.

Various parameters have been taken into account while estimating market size. The revenue generated by the leading industry participants in from the sales of Oral Anti-diabetic Drugs across the world has been calculated through primary and secondary research.

Zion Market Research employs the combination of secondary research followed by extensive primary research. Under secondary research, we refer to prominent paid as well as open access data sources including product literature, company annual reports, government publications, press releases, industry association’s magazines and other relevant sources for data collection. Other prominent secondary sources include STATISTA, trade journals, trade associations, statistical data from government websites, etc. 

For this study, Zion Market Research has conducted all-encompassing primary research with key industry participants to collect first had data. Moreover, in-depth interviews with key opinion leaders also assisted in the validation of findings from secondary research and to understand key trends in the Oral Anti-diabetic Drugs industry. Primary research makes up the major source of data collection and validation.   

Primary Research

We conduct primary interviews with industry participants and commentators on an ongoing basis to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides firsthand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening the secondary research findings
  • Further, develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies

Participants who typically participate in such a process include, but are not limited to:

  • Industry participants: CEOs, VPs, marketing/product managers, market intelligence managers and national sales managers
  • Purchasing managers, technical personnel, distributors and resellers
  • Outside experts: Investment bankers, valuation experts and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

Secondary Research

Secondary research sources that are typically referred to include, but are not limited to:

  • Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
  • IDC and other relevant magazines
  • Internal and external proprietary databases, and relevant patent and regulatory databases
  • National government documents, statistical databases and market reports

News articles, press releases and webcasts specific to companies operating in the market

Following a comprehensive secondary and primary research and insights thus gathered, analysts at Zion Research have provided an in-depth analysis of various aspects of the Oral Anti-diabetic Drugs market.

Models

Where no hard data is available, we use models and estimates to produce comprehensive data sets. A rigorous methodology is adopted, wherein the available hard data is cross-referenced with the following data types to produce estimates:

  • Demographic data: Population split by segments
  • Macroeconomic indicators: GDP, PPP, Per Capita Income, etc.
  • Industry indicators: Expenditure, technology stage and infrastructure, sector growth and facilities
  • Data is then cross-checked by an expert panel.

Free Analysis

Diabetes is a group of metabolic disorder characterized by the presence of high blood glucose level than normal level in an individual. The rise of blood glucose is due to inadequate insulin production, or because the body's cells do not respond properly to insulin. Diabetes is broadly characterized into two types: Insulin-dependent diabetes mellitus (type 1) and Non-insulin dependent diabetes mellitus (type 2). Various initial symptoms associated with diabetes include increasing thirst, frequent urination, fatigue, weight and muscle loss, delayed wound healing and blurred vision.

The global rise in oral anti-diabetic drug market is mainly due to increase in the prevalence of diabetic patient across the globe. According to WHO, the number of people with diabetes has risen from 108 million in 1980 to 422 million in 2014. This rise is continuously seen in developing countries like India and China. Moreover, the factors which are responsible for increasing numbers of the diabetic population globally include sedentary lifestyles, obesity, the rise in geriatric populations and poor healthcare services. However, a high cost of the drug is expected to restraint the growth of global oral anti-diabetic drug market. Nonetheless, huge market strength and untapped market of Asia Pacific and Africa market considered as a major opportunity for upcoming manufacturers of global oral anti-diabetic drug markets.

Global-Oral-Antidiabetic-Drug-Market

Based on the class of drug, the global oral anti-diabetic drug market is segmented into five types: sulfonylureas, meglitinides, biguanides, alpha-glucosidase inhibitors and others. Sulphonylureas segment of oral anti-diabetic drug market accounted for the largest market share in 2016 followed by biguanides derivatives. In 2016, Sulphonylureas accounted for about 37% share of the total oral anti-diabetic market. The growth is attributed due to the availability of low cost of drugs under this segment. A drug under this category includes glimepiride, gliclazide, glyburide and others. Whereas, Biguanides derivatives account for the second largest shares in the total oral anti-diabetic market followed by alpha-glucosidase inhibitors. Metformin is a biguanide class which is most preferred oral anti-diabetics drug currently prescribed by a physician for the treatment of Type 2 diabetes mellitus.

Key market players of oral anti-diabetic drug market include Eli Lilly, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck and Pfizer.

Choose License Type

Request the coronavirus impact analysis across industries and markets

FrequentlyAsked Questions

The global Oral antidiabetic drugs Market was valued at USD 43.01 Billion in 2020.

The global Oral antidiabetic drugs Market is expected to reach USD 66.30 Billion by 2028, growing at a CAGR of 5.6% between 2021 to 2028.

Oral antidiabetic drugs Market is expected to grow tremendously owing to growing prevalence of kidney disease sand urinary tract infections. The growing occurrence of target diseases, such as Urinary Tract Infections (UTI), kidney diseases, and diabetes with the increase in the new advanced technology, rapid, non-invasive, and user-friendly tools for urinalysis are projected to be the major growth drivers of this market.

North America region held a substantial share of the Oral antidiabetic drugs Market in 2020.

Some of the major companies operating in the Oral antidiabetic drugs Market are Sanofi S.A., Eli Lilly and Company, AstraZeneca plc, Astellas Pharma Inc., Johnson & Johnson (Janssen Pharmaceuticals), Boehringer Ingelheim, Merck And Co., Takeda, Bristol Myers Squibb, Novartis, Pfizer.

HappyClients

Office Address

Contact Us

Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed